Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for idiopathic retroperitoneal fibrosis
ACTRN12618000922279Phase 2Not yet recruiting
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab in Idiopathic retroperitoneal fibrosis (RPF), sponsored by Azienda Ospedaliero-Universitaria di Parma. Primary endpoint: Remission at month 6. Planned start Jul 2018; status: not yet recruiting.
02
Drugs
tocilizumab
03
Conditions
Idiopathic retroperitoneal fibrosis (RPF)
Beyond the preview
Go deeper on ACTRN12618000922279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000922279.